{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:13:12Z","timestamp":1788243192932,"version":"build-2803163510"},"reference-count":29,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"DOI":"10.1210\/jc.2008-2765","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T22:23:49Z","timestamp":1246400629000},"page":"3215-3225","source":"Crossref","is-referenced-by-count":95,"title":["Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density"],"prefix":"10.1210","volume":"94","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[{"name":"Academic Unit of Bone Metabolism (R.E.), University of Sheffield, Sheffield S5 7AU, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics (D.M.B., L.P.), University of California at San Francisco, San Francisco, California 94107"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[{"name":"Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine (S.B.), Katholieke Universiteit Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[{"name":"Rheumatology Unit (S.A.), University of Verona, Ospedale Maggiore, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[{"name":"Centre of Muscle and Bone Research (D.F.), Free University and Humboldt-University, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Lippuner","sequence":"additional","affiliation":[{"name":"Osteoporosis Policlinic (K.L.), University Hospital and University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Cummings","sequence":"additional","affiliation":[{"name":"San Francisco Coordinating Center (S.R.C.), University of California, San Francisco, California 94107"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale Research Unit 831 and University of Lyon (P.D.D.), 69437 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Palermo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics (D.M.B., L.P.), University of California at San Francisco, San Francisco, California 94107"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mesenbrink","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation (P.M.), East Hanover, New Jersey 07936"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Cauley","sequence":"additional","affiliation":[{"name":"Department of Epidemiology (J.A.C.), University of Pittsburgh, Pittsburgh, Pennsylvania 15261"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HORIZON Pivotal Fracture Trial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113431844800_R1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density.","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113431844800_R2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113431844800_R3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bmj.309.6956.691","article-title":"Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study.","volume":"309","author":"Jones","year":"1994","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113431844800_R4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019041113431844800_R5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.","volume":"54","author":"Boonen","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019041113431844800_R6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","article-title":"Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.","volume":"21","author":"Seeman","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113431844800_R8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113431844800_R9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.","volume":"19","author":"Chesnut III","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1359\/JBMR.041007","article-title":"Osteoporosis and fracture risk in women of different ethnic groups.","volume":"20","author":"Barrett-Connor","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R11","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial.","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113431844800_R12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures.","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis.","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113431844800_R14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures.","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"issue":"1 Suppl","key":"key\n\t\t\t\t2019041113431844800_R15","doi-asserted-by":"crossref","first-page":"57S","DOI":"10.1016\/8756-3282(95)00381-9","article-title":"Epidemiology of hip fractures","volume":"18","author":"Kannus","year":"1996","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113431844800_R16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis.","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113431844800_R17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00198-006-0209-8","article-title":"Use of clinical risk factors to identify postmenopausal women with vertebral fractures.","volume":"18","author":"Tobias","year":"2007","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113431844800_R18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00198-007-0510-1","article-title":"Rate and circumstances of clinical vertebral fractures in older men.","volume":"19","author":"Freitas","year":"2008","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113431844800_R19","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1001\/jama.288.18.2300","article-title":"Walking and leisure-time activity and risk of hip fracture in postmenopausal women.","volume":"288","author":"Feskanich","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113431844800_R20","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-005-1903-7","article-title":"In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml\/min is a risk factor for falls and fractures.","volume":"16","author":"Dukas","year":"2005","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113431844800_R21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113431844800_R23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1359\/jbmr.1999.14.1.90","article-title":"Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group.","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R24","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine \u2013 reporting of subgroup analyses in clinical trials.","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113431844800_R25","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","article-title":"Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.","volume":"157","author":"Ensrud","year":"1997","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113431844800_R26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women\u2019s Health Initiative Randomized Trial.","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R27","first-page":"375","article-title":"Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment.","volume":"21","author":"Coen","year":"1995","journal-title":"Miner Electrolyte Metab"},{"key":"key\n\t\t\t\t2019041113431844800_R28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1359\/jbmr.2005.20.1.131","article-title":"Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures.","volume":"20","author":"Nevitt","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113431844800_R29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/9\/3215\/9064722\/jcem3215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:46:29Z","timestamp":1558399589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/9\/3215\/2596546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-2765","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]}}}